Globeflex Capital’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.23M Sell
349,651
-102,955
-23% -$664K 0.34% 87
2025
Q4
$2.69M Hold
452,606
0.41% 76
2025
Q3
$2.4M Hold
452,606
0.37% 79
2025
Q2
$1.55M Hold
452,606
0.13% 142
2025
Q1
$1.34M Hold
452,606
0.12% 141
2024
Q4
$1.38M Hold
452,606
0.12% 152
2024
Q3
$1.15M Hold
452,606
0.11% 165
2024
Q2
$1.48M Sell
452,606
-39,145
-8% -$172K 0.15% 140
2024
Q1
$2.61M Sell
491,751
-46,808
-9% -$252K 0.25% 97
2023
Q4
$2.33M Hold
538,559
0.24% 106
2023
Q3
$1.42M Sell
538,559
-22,971
-4% -$78.2K 0.17% 140
2023
Q2
$1.98M Hold
561,530
0.22% 118
2023
Q1
$1.74M Hold
561,530
0.21% 120
2022
Q4
$2.38M Sell
561,530
-9,310
-2% -$32.1K 0.3% 86
2022
Q3
$1.35M Buy
570,840
+151,518
+36% +$442K 0.23% 132
2022
Q2
$1.2M Buy
419,322
+69,098
+20% +$172K 0.29% 98
2022
Q1
$1.01M Sell
350,224
-63,157
-15% -$163K 0.2% 138
2021
Q4
$1.26M Sell
413,381
-311
-0.1% -$1.35K 0.26% 119
2021
Q3
$2.9M Sell
413,692
-34,009
-8% -$255K 0.63% 26
2021
Q2
$4.11M Buy
447,701
+19,021
+4% +$193K 0.74% 15
2021
Q1
$4.17M Buy
428,680
+373,653
+679% +$4.17M 0.76% 15
2020
Q4
$565K Hold
55,027
0.12% 269
2020
Q3
$555K Sell
55,027
-8,199
-13% -$83.5K 0.15% 228
2020
Q2
$659K Buy
+63,226
New +$654K 0.17% 219

Other funds holding PBYI

Globeflex Capital's PBYI Position: Q1 2026 in Review

Globeflex Capital reduced its Puma Biotechnology (PBYI) stake by 23% in Q1 2026, selling an estimated $664K and leaving 349,651 shares worth $2.23M. The position accounts for 0.34% of the portfolio, ranked #87.

Globeflex Capital first reported a position in PBYI in Q2 2020 and has held it in 24 quarters since. The position peaked at $4.17M in Q1 2021. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Globeflex Capital held 349,651 shares of Puma Biotechnology worth $2.23M as of Q1 2026.
  • Globeflex Capital sold 102,955 Puma Biotechnology shares in Q1 2026, an estimated $664K.
  • Puma Biotechnology made up 0.34% of Globeflex Capital's portfolio in Q1 2026, its #87 holding.
  • Globeflex Capital first reported a position in Puma Biotechnology in Q2 2020 and has held it in 24 quarters since.
  • Globeflex Capital's Puma Biotechnology position peaked at $4.17M in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.